(Q41348490)

29 September 2017

1 reference

title

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. (English)

1 reference

29 September 2017

Haria M

1

1 reference

PubMed ID

9028747

29 September 2017

McTavish D

series ordinal

2

1 reference

29 September 2017

1 February 1997

1 reference

29 September 2017

1 reference

29 September 2017

53

1 reference

29 September 2017

299-336

1 reference

29 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199753020-00008

29 September 2017

0 references

cites work

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

1 reference

12 December 2020

Apparent discontinuation rates in patients prescribed lipid-lowering drugs.

1 reference

12 December 2020

Pravastatin decreases serum lipids and vascular cholesterol deposition in Watanabe heritable hyperlipidemic (WHHL) rabbits

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients

1 reference

12 December 2020

Steady state serum concentrations of pravastatin and digoxin when given in combination

1 reference

12 December 2020

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

1 reference

12 December 2020

Replacing lovastatin with pravastatin: effect on serum lipids and costs.

1 reference

12 December 2020

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.

1 reference

12 December 2020

Pravastatin (mevalotin) restenosis trial after percutaneous transluminal coronary angioplasty. Cholesterol reduction rate determines the restenosis rate

1 reference

12 December 2020

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

1 reference

12 December 2020

Cholesterol and mortality. 30 years of follow-up from the Framingham study.

1 reference

12 December 2020

Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels

1 reference

12 December 2020

Decreased albuminuria by pravastatin in hyperlipidemic diabetics

1 reference

12 December 2020

In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

1 reference

12 December 2020

Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.

1 reference

12 December 2020

Pravastatin experience in elderly and non-elderly patients

1 reference

12 December 2020

Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration

1 reference

12 December 2020

Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.

1 reference

12 December 2020

Pharmacokinetics of pravastatin in elderly versus young men and women.

1 reference

12 December 2020

Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine

1 reference

12 December 2020

Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia.

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin.

1 reference

12 December 2020

Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration

1 reference

12 December 2020

Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II

1 reference

12 December 2020

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

12 December 2020

Effect of food on pravastatin pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia

1 reference

12 December 2020

Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin

1 reference

12 December 2020

Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group

1 reference

12 December 2020

Clinical evaluation of pravastatin in the treatment of type II hyperlipidemia in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

George Lyman Duff Memorial Lecture. Atherogenesis in diabetes.

1 reference

12 December 2020

Safety of combined pravastatin-gemfibrozil therapy

1 reference

12 December 2020

Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators.

1 reference

12 December 2020

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group

1 reference

12 December 2020

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

1 reference

12 December 2020

Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidemic rabbits.

1 reference

12 December 2020

Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test

1 reference

12 December 2020

Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin

1 reference

12 December 2020

The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.

1 reference

12 December 2020

Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries.

1 reference

12 December 2020

Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia

1 reference

12 December 2020

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

1 reference

12 December 2020

Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens

1 reference

12 December 2020

Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation

1 reference

12 December 2020

The effect of pravastatin in relation to low density lipoprotein receptor activity

1 reference

12 December 2020

Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease.

1 reference

12 December 2020

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.

1 reference

12 December 2020

Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia

1 reference

12 December 2020

Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

1 reference

12 December 2020

Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.

1 reference

12 December 2020

Does lowering of cholesterol levels influence functional properties of large arteries?

1 reference

12 December 2020

Change in cholesterol awareness and action. Results from national physician and public surveys

1 reference

12 December 2020

Management of dyslipidemia in NIDDM.

1 reference

12 December 2020

Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor

1 reference

12 December 2020

Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Re

1 reference

12 December 2020

Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia

1 reference

12 December 2020

Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus. Hyogo Pravastatin Study Group.

1 reference

12 December 2020

Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia

1 reference

12 December 2020

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

12 December 2020

Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier

1 reference

12 December 2020

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

12 December 2020

An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence

1 reference

12 December 2020

Effect of pravastatin on human sleep.

1 reference

12 December 2020

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.

1 reference

12 December 2020

1 reference

12 December 2020

Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

1 reference

12 December 2020

Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia.

1 reference

12 December 2020

Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group

1 reference

12 December 2020

Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience

1 reference

12 December 2020

Long-term experience with pravastatin in clinical research trials.

1 reference

12 December 2020

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin

1 reference

12 December 2020

The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.

1 reference

12 December 2020

Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels

1 reference

12 December 2020

Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.

1 reference

12 December 2020

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.

1 reference

12 December 2020

[Rhabdomyolysis caused by pravastatin and type 1 macrocreatine kinase]

1 reference

12 December 2020

Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits

1 reference

12 December 2020

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

1 reference

12 December 2020

Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.

1 reference

12 December 2020

Relative safety and efficacy of pravastatin

1 reference

12 December 2020

Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter.

1 reference

12 December 2020

Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs

1 reference

12 December 2020

Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.

1 reference

12 December 2020

Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin

1 reference

12 December 2020

Successful dissolution of cholesterol gallstone during treatment with pravastatin

1 reference

12 December 2020

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.

1 reference

12 December 2020

Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.

1 reference

12 December 2020

Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine.

1 reference

12 December 2020

Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I

1 reference

12 December 2020

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.

1 reference

12 December 2020

Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

1 reference

12 December 2020

Is vascular smooth muscle cell proliferation beneficial?

1 reference

12 December 2020

Cholesterol screening in asymptomatic adults, revisited. Part 2.

1 reference

12 December 2020

Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.

1 reference

12 December 2020

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholester

1 reference

12 December 2020

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients

1 reference

12 December 2020

The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects

1 reference

12 December 2020

Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits

1 reference

12 December 2020

Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone

1 reference

12 December 2020

Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression.

1 reference

12 December 2020

Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance

1 reference

12 December 2020

Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy.

1 reference

12 December 2020

Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

1 reference

12 December 2020

Prevention of restenosis by lovastatin after successful coronary angioplasty

1 reference

12 December 2020

The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group.

1 reference

12 December 2020

Management of hyperlipidemia of kidney disease.

1 reference

12 December 2020

Lipids and progressive kidney disease.

1 reference

12 December 2020

Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin

1 reference

12 December 2020

Epidemiology of hypercholesterolemia and European management guidelines

1 reference

12 December 2020

The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl

1 reference

12 December 2020

Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).

1 reference

12 December 2020

Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a

1 reference

12 December 2020

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

12 December 2020

Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study

1 reference

12 December 2020

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1 reference

12 December 2020

Low-density lipoprotein density and atherosclerosis. Unraveling the connection.

1 reference

12 December 2020

Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.

1 reference

12 December 2020

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

1 reference

12 December 2020

Effects of lovastatin and pravastatin on sleep efficiency and sleep stages.

1 reference

12 December 2020

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

The economics of cholesterol lowering.

1 reference

12 December 2020

Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome

1 reference

12 December 2020

Clinical implications of new drugs for lowering plasma cholesterol concentrations.

1 reference

12 December 2020

Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment

1 reference

12 December 2020

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1 reference

12 December 2020

Pravastatin and lovastatin in cerebrospinal fluid

1 reference

12 December 2020

Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment

1 reference

12 December 2020

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.

1 reference

12 December 2020

Atherosclerosis and lipoprotein metabolism: role of reverse cholesterol transport.

1 reference

12 December 2020

Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years.

1 reference

12 December 2020

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

1 reference

12 December 2020

Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia.

1 reference

12 December 2020

The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group.

1 reference

12 December 2020

Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries

1 reference

12 December 2020

Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.

1 reference

12 December 2020

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

1 reference

12 December 2020

Different effects of the hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo

1 reference

12 December 2020

Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens

1 reference

12 December 2020

Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts.

1 reference

12 December 2020

Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.

1 reference

12 December 2020

Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia

1 reference

12 December 2020

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia

1 reference

12 December 2020

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

1 reference

12 December 2020

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

12 December 2020

Pravastatin-associated inflammatory myopathy

1 reference

12 December 2020

Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens.

1 reference

12 December 2020

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing

1 reference

12 December 2020

The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy.

1 reference

12 December 2020

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.

1 reference

12 December 2020

Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia.

1 reference

12 December 2020

Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats

1 reference

12 December 2020

Preclinical evaluation of lovastatin.

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

1 reference

12 December 2020

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia

1 reference

12 December 2020

Pravastatin: interaction with oral anticoagulant?

1 reference

12 December 2020

Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers.

1 reference

12 December 2020

A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational Study Group for Diabetes

1 reference

12 December 2020

Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia

1 reference

12 December 2020

Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits

1 reference

12 December 2020

Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.

1 reference

12 December 2020

The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.

1 reference

12 December 2020

Effects of pravastatin in dyslipidaemic patients with and without hypertension

1 reference

12 December 2020

Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia

1 reference

12 December 2020

Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group

1 reference

12 December 2020

Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study

1 reference

12 December 2020

Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.

1 reference

12 December 2020

Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers.

1 reference

12 December 2020

Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin

1 reference

12 December 2020

Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease

1 reference

12 December 2020

Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group.

1 reference

12 December 2020

Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model

1 reference

12 December 2020

[Effectiveness of pravastatin and bezafibrate in primary hypercholesterolemia]

1 reference

12 December 2020

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

12 December 2020

Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia

1 reference

12 December 2020

Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group

1 reference

12 December 2020

The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Pravastatin--ocular side effects after a two year follow-up?

1 reference

12 December 2020

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

12 December 2020

Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). The European Study Group

1 reference

12 December 2020

Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects

1 reference

12 December 2020

Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients

1 reference

12 December 2020

Statins and coronary heart disease

1 reference

12 December 2020

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species.

1 reference

12 December 2020

Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia

1 reference

12 December 2020

The effects of pravastatin on hyperlipidemia in renal transplant recipients

1 reference

12 December 2020

Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern

1 reference

12 December 2020

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group

1 reference

12 December 2020

Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin

1 reference

12 December 2020

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.

1 reference

12 December 2020

Pharmaco-economic assessment of the HMG-CoA reductase inhibitors

1 reference

12 December 2020

Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.

1 reference

12 December 2020

10.2165/00003495-199753020-00008

Identifiers

DOI

1 reference

PubMed ID

9028747